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 ABSTRACT 
 
Setting: Isoniazid-resistant rifampicin-susceptible (HRRS) tuberculosis (TB) is 
the most prevalent form of drug-resistant TB globally, and may be a risk factor 
for poor outcomes. HRRS-TB in children has been poorly described. 
 
Objective:  To characterize the clinical presentation, treatment, and clinical 
and microbiological outcomes, and factors associated with poor outcomes 
among children with culture-confirmed HRRS-TB. 
 
Design:  Retrospective hospital-based cohort study. 
 
Results:  Of the 72 children included, median age 50.1 months (IQR 21.5-
102.5), 42% were male.  Forty-four (51%) had a potential source case; only 
13 were confirmed HRRS-TB. Twelve of 66 tested (17%) were HIV-infected, 
and 36 of 60 (60%) with pulmonary TB had severe disease. Seventy had 
treatment data; median total duration was 11.3 months (IQR 9-12.3); 25 
(36%) initiated treatment with a 3-drug intensive phase; 52 (74%) received a 
fluoroquinolone.  Of 63 with known outcome, 55 (88%) had a favourable 
outcome; 1 died and 3 had treatment failure.  Ten had positive follow-up 
cultures at ≥2 months after starting treatment (17% of all PTB and 27% of 
those with follow-up culture data); older age (p=0.008), previous TB treatment 
(p=0.023) and severe PTB (p=0.018) were associated with failure to culture-
convert at ≥2 months. 
 
Conclusions: Although overall outcomes were good, prolonged culture 
positivity and cases of treatment failure emphasize the need for additional 
attention to clinical management of children with HRRS-TB. 
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INTRODUCTION 
 
Children account for 10-15% of the global tuberculosis (TB) disease burden,1 
resulting in an estimated 550,000 to 1,000,000 cases yearly, and an estimated 
80,000 deaths in HIV-uninfected children globally in 2013.2, 3  Substantial resources 
are being invested in addressing the global problem of multidrug-resistant (MDR)-
TB, defined as Mycobacterium tuberculosis resistant to isoniazid (INH) and 
rifampicin (RIF), however limited attention has been given to TB that is INH-resistant 
but RIF-susceptible (HRRS-TB).   
 
The 2014 Global TB Report of the World Health Organization (WHO) estimated that 
HRRS-TB represented on average 9.5% of all cases, including 8.1% of new cases 
and 14.0% of previously treated cases, with substantial regional variation.2  Data on 
HRRS-TB prevalence in children is limited.  Recent estimates suggest that 12.1% of 
incident TB cases in children globally were INH-resistant in 2010, with many of these 
likely being HRRS depending on the setting.4  In Cape Town, South Africa, ongoing 
enhanced hospital-based surveillance showed that between 2003-2011, 5.1-7.7% of 
children <13 years with culture-confirmed TB had HRRS-TB.5 
 
With a high early bactericidal activity, INH is responsible for a rapid initial reduction in 
mycobacterial burden, potentially decreasing patients’ infectiousness, hastening 
clinical improvement,6, 7 and protecting against resistance development in other 
drugs in the regimen.7  Current adult and paediatric guidelines recommend treating 
HRRS-TB with 6-12 months of RIF, pyrazinamide (PZA), and ethambutol (EMB), 
with the addition of a fluoroquinolone for extensive disease.8-12  Evidence for these 
recommendations is low quality, and no controlled trials have evaluated regimens for 
HRRS-TB in adults or children.13, 14  A systematic review and meta-analysis showed 
variable but substantial rates of treatment failure, relapse, and acquired drug 
resistance in adults with HRRS-TB .15  Children with HRRS-TB may be at particular 
risk for poor treatment outcomes as they may be treated with a standard 3 drug 
intensive phase containing RIF, INH, and PZA, (RHZ) which is likely inadequate in 
the context of INH resistance.  The clinical presentation, treatment, and outcomes of 
children with HRRS-TB are poorly described,16 and more data on this important TB 
disease entity in children is needed. 
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The Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA), a new molecular diagnostic 
tool for rapid detection of TB and RIF resistance in clinical specimens,17 is 
increasingly used globally for TB diagnosis, including in children.18 19 The inability to 
test for INH resistance means the roll-out of Xpert MTB/RIF may have important 
implications for the detection and management of HRRS-TB in children, since this 
entity would be under-detected using Xpert MTB/RIF only. 
 
This study aimed to characterize the clinical presentation, treatment and clinical and 
microbiological outcomes in children with culture-confirmed HRRS-TB; we also 
investigate factors associated with poor treatment outcomes. 
 
STUDY POPULATION AND METHODS 
 
Study Design 
Retrospective hospital-based cohort study. 
 
Setting and patient management 
This study was undertaken at three hospitals in the Western Cape Province, South 
Africa, where the TB notification rate was 954.1 cases per 100,000 population in 
2010.20  Tygerberg Children’s Hospital (TCH) is a large provincial referral centre for 
children, where, as part of ongoing surveillance, a database of all routine culture-
confirmed TB in children is maintained.  Brooklyn Hospital for Chest Diseases 
(BHCD) is a specialized TB hospital which cares for children with drug-resistant-TB, 
TB meningitis (TBM) and children who need social support.  Brewelskloof Hospital 
(BKH) is a regional TB hospital managing the long-term treatment of drug-resistant 
TB patients, including children.  
 
Mycobacterial cultures were routinely performed at the South Africa National Health 
Laboratory Service (NHLS) laboratories, according to a standardized protocol using 
Middlebrook 7H9 broth base (Mycobacteria Growth Indicator Tubes [MGIT]; Becton 
Dickinson, Sparks, MD, USA).  Before August 2008, drug susceptibility testing (DST) 
was done with the Bactec 460TB System (Becton-Dickinson, Sparks, MD, USA) 
according to international norms.  INH was tested at a concentration of 0.1 µg/ml and 
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RIF at 2.0 µg/mL, with resistance defined as ≥1% bacterial growth in drug-containing 
compared to non-drug-containing media.  After August 2008, DST was done using 
the line-probe assay (LPA; GenoType® MTBDRplus, Hain Lifescience, Nehren, 
Germany). 
 
Children with uncomplicated HRRS-TB were generally managed in the community, 
with 6-9 months of all four drugs RHZE (RIF, INH, PZA, EMB, with number before 
the abbreviation indicating months) for the full duration of treatment, per national 
South African guidelines.10  Children with severe disease or poor response to 
treatment were typically referred for specialist consultation and prescription of more 
complex regimens, which in addition to RHZE could include a fluoroquinolone, 
ethionamide, and/or terizidone.  As most children were treated with fixed-dose 
combination tablets of the first-line TB drugs, INH was most often included in the 
regimen, usually at a higher dose (15-20mg/kg, up to 400mg).  Repeat respiratory 
cultures were recommended but were variably done based on clinical practice and 
ability to collect respiratory samples in children in different clinical settings.  Local 
guidelines recommend 6-9 months of INH, RIF, PZA and ethionamide for all cases of 
TB meningitis (TBM). 
 
Study population 
Children were included if they were <13 years of age, routinely diagnosed or 
managed at any of the three study hospitals, and had a culture from any clinical 
specimen positive for M. tuberculosis, with DST demonstrating INH-resistance and 
RIF-susceptibility, between January 1, 2006 through December 31, 2011. 
 
Data collection 
Potentially eligible patients were identified from the ongoing routine surveillance at 
the 3 hospitals. For identified patients, medical records were reviewed and relevant 
data extracted using a standard form.  Mantoux tuberculin skin test (TST) results 
were considered positive if ≥5mm in HIV-infected children and ≥10mm in HIV-
uninfected children.  Previous treatment was considered receipt of TB medications 
for disease or preventive therapy. TB was classified according to site of disease as 
pulmonary, extrapulmonary, or both, and the severity of disease was categorized 
according to consensus classification of TB disease severity in children.21  Weight-
Stellenbosch University  https://scholar.sun.ac.za
  4 
for-age Z-scores (WAZ) were calculated using the 1990 British growth reference, as 
WHO growth references only include children up to 10 years of age.22  TB treatment 
outcomes were classified as either “Favourable”, which included cure, probable cure, 
and treatment completion,23 or “Unfavourable”.23  Children with positive cultures at 
month 5 of treatment were considered to have treatment failure, even if they 
ultimately completed treatment successfully. 
 
Analysis 
Demographic, clinical and treatment characteristics and outcomes were summarized 
using descriptive statistics.  Associations between clinically relevant characteristics 
with unfavourable outcome and with a positive culture at ≥2 months, were assessed 
with chi-square or Fisher’s exact tests for categorical variables, and t-test or 
Wilcoxon rank sum test for continuous variables.  Assessed characteristics included 
age, gender, previous treatment, WAZ, TB type, HIV-infection, disease severity, 
acid-fast bacilli (AFB) smear positivity (respiratory specimens), INH resistance 
mutation, and treatment with >1 month of RHZ.  Analyses were performed using 
Stata version 12.0 (Stata Corp, College Station, TX, USA). 
 
Ethics 
Approval for the study was provided by the Stellenbosch University Faculty of 
Medicine and Health Sciences Health Research Ethics Committee (S12/06/184).  
 
RESULTS 
 
Seventy-two children were included; sixty (83%) from TCH, 9 (13%) from BHCD, and 
3 (4%) from BKH.  Key characteristics at diagnosis are shown in table 1.  Seventeen 
(24%) children had 19 previous TB treatment episodes (INH preventive therapy in 
four, standard drug-susceptible TB treatment for TB disease in ten, treatment for 
multidrug-resistant TB in one and unknown in four).  Cases treated in the year prior 
to their HRRS-TB episode are described in table 2. 
 
Seventy of 72 (97%) had treatment data recorded, with 63 (88%) having data on 
their entire treatment regimen. Regimens were highly variable in content and 
duration; key treatment characteristics are listed in table 3.  Many children started 
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treatment with a three-drug intensive phase (RHZ), including 10 of 36 (28%) children 
with severe pulmonary TB (PTB) on their initial chest radiograph.  Fifty-two children 
(74%) received fluoroquinolones with or without additional second-line TB 
medications; at least a proportion of these were started on MDR-TB treatment 
empirically because of a known MDR-TB source case or a concern for acquired drug 
resistance during inadequate treatment for HRRS-TB. 
 
Eleven (15%) children were treated for TBM, four of whom had cerebrospinal fluid 
(CSF) culture positive for HRRS-TB, six with Stage 2 and four with Stage 3 TBM. All 
were started on a four-drug regimen of high-dose INH, RIF, PZA, and ethionamide; 
10 of 11 had a fluoroquinolone with or without terizidone added to their regimen 
within two months of treatment initiation. One died (table 2), but all other TBM cases 
had favourable outcome.   
 
Sixty-three (88%) children had data on final TB treatment clinical outcomes; 55 of 63 
(88%) were favourable (table 3).  The one death and three treatment failures are 
described in more detail in table 2.  Of the 60 with PTB, 37 had follow-up cultures on 
respiratory specimens after initiating treatment; the percentage of positive cultures at 
each month is shown in figure 1. Ten children had a positive follow-up culture at ≥2 
months after starting treatment, representing 17% of all those with PTB and 27% of 
those with a follow-up culture.  Three children accounted for the five positive culture 
results three months or more after starting treatment.   
 
In univariable analysis, no characteristics were associated with unfavourable 
outcome; older age (p=0.008), documented previous TB treatment (p=0.023) and 
severe PTB (p=0.018) were associated with positive follow-up cultures at ≥2 months 
after treatment initiation (table 4). 
 
DISCUSSION 
 
In this large cohort of children with culture-confirmed HRRS-TB, overall clinical 
outcomes were good.  However a number of children had prolonged culture positivity 
and treatment failure, emphasizing the need for additional attention to clinical 
management of this subgroup of children with TB. To our knowledge, the largest 
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report to date is a single case series of 26 children treated for HRRS-TB in New York 
between 1961 and 1972.16  One child died, but the remaining patients completed 
treatment with good outcomes. The relevance of that study to current practice is 
limited, as the majority were treated without RIF or PZA, and received variable three 
and four drug combinations of INH, para-aminosalicylic acid (PAS), streptomycin, 
RIF, EMB, ethionamide and cycloserine.16 The cohort we report here provides data 
on the clinical presentation, treatment, and outcomes of a substantial number of 
children with HRRS-TB, which reflects currently available drug regimens in global 
settings.  
 
In our study, just over 60% of children had a known potential TB source case, 
consistent with children with culture-confirmed TB in our context.5  However, only 
24% of the potential source cases had confirmed HRRS-TB.  The potential MDR-TB 
source cases reported in eight patients may reflect infection of the child with HRRS 
M.tuberculosis prior to the source case’s acquisition of additional RIF resistance.  
The majority of the adult source cases had unknown drug-susceptibility.  Clinical 
records however frequently indicated that source cases were retreatment cases or 
were on an injectable (indicating a retreatment regimen or MDR-TB); this was 
difficult to quantify, but it is likely that a substantial portion of those source cases with 
unknown drug-susceptibility were in fact HRRS-TB.  The high proportion of source 
cases with unknown drug-susceptibility may have contributed to delayed initiation of 
an appropriate treatment regimen in child contacts.  In keeping with this concern, 
36% of children in our cohort were initially started on a 3-drug intensive phase with 
RHZ. However, the presence of a known source case was not a risk factor for having 
an unfavourable outcome or prolonged culture positivity. With the roll-out of Xpert 
MTB/RIF test as the initial diagnostic test for TB, information regarding the INH 
resistance of source cases is likely to become less available. This has important 
implications for the prophylaxis and treatment of children exposed to adults with 
HRRS-TB. 
 
As would be expected for hospital-based cohorts, children in this study had 
significant clinical disease with 50% being underweight (WAZ<-2), 60% of those with 
PTB having severe disease, and 45% of those tested being AFB sputum smear-
positive. The proportion with severe PTB in our cohort is comparable to children with 
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culture-confirmed MDR-TB from the same setting (45.9% with severe chest 
radiograph findings),24 although the case definitions differed slightly between the two 
studies. The high proportion of severe disease in our study may reflect delays in 
presentation and initiation of appropriate treatment. 
 
Treatment regimens were highly variable and difficult to classify.  The long treatment 
duration was likely related to the observed severity of disease, as well as a 
conservative approach taken given concern about potentially acquired resistance 
during periods of inadequate treatment.  However, the duration of treatment with a 
regimen appropriate to HRRS-TB was within the recommended range (6-12 months) 
for most patients.   
 
A substantial risk of treatment failure and acquired drug resistance in adults with 
HRRS-TB has been reported in adults receiving standard short course 
chemotherapy and in those treated with RHZE.25, 26  Conclusions about the most 
appropriate regimen or treatment duration for HRRS-TB in children should be drawn 
cautiously from our study, which was observational and had no control arm.  
Children treated with a fluoroquinolone may have done equally well with a less 
intensive regimen such as 6RHZE, and shorter treatment durations may have been 
as effective.  However, given increasing concerns about low RIF exposures in 
children,27, 28 and a growing body of evidence regarding fluoroquinolone safety in 
children,29, 30 the addition of a fluoroquinolone may be reasonable.  It is important to 
note that children in this cohort treated with the long durations and fluoroquinolone-
containing regimens had good outcomes, despite having severe disease.  
 
Microbiological outcomes in children treated for TB have not been well described.  A 
substantial proportion of children in our cohort had positive cultures at one and two 
months after initiating TB treatment; of 37 patients with at least one follow-up culture, 
10 (27%) had positive cultures at ≥2 months.  In a cohort of children with MDR-TB in 
our setting, 9 of 41 (22%) with bacteriological confirmation remained culture-positive 
at 2 months.29 The three patients with failed treatment and prolonged culture 
positivity (table 2) are particularly concerning. Poor adherence cannot be ruled out 
as a cause of the prolonged culture-positivity, however this delayed treatment 
response is unusual in cases with drug-susceptible TB in our experience.  The child 
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with acquisition of rifampicin-resistance and progression of disease on inadequate 
treatment has been described in detail elsewhere,31 and highlights the potential risk 
for children with HRRS-TB inadequately treated. Our cohort received highly 
individualized treatment; in settings where there is limited access to culture and DST 
and children with HRRS-TB may receive standard short-course regimens, outcomes 
may not be as good.  We suspect the four patients treated with standard drug-
susceptible TB treatment in the months prior to their HRRS-TB episode likely had 
HRRS-TB in their first episode, which then relapsed (table 2); this provides additional 
evidence of poor treatment response. 
 
HRRS-TBM may be particularly problematic to treat, due to poor penetration of RIF 
and EMB into CSF, and some adult data suggest a worse outcome compared to 
drug-susceptible TBM.32 The favourable outcomes in children with HRRS-TBM in our 
cohort may be related to the empiric regimen for TBM in use in our setting, which 
includes higher doses of INH and RIF, and ethionamide, which has excellent CSF 
penetration.  The majority of children with TBM in this cohort also received a 
fluoroquinolone with or without terizidone, both of which have good CSF penetration. 
Fluoroquinolones are being investigated for their potential to improve TBM outcomes 
in adults.33 
 
In univariable analysis there were no statistically significant associations with 
unfavourable treatment outcomes. However, older age, previous treatment, and 
severe PTB were associated with culture positivity at ≥2 months’ treatment.  We 
hypothesize that this is driven primarily by disease severity.  Older age was 
associated with severe PTB, and older children have a well-described higher risk of 
developing adult-type disease.34  Previous treatment was also associated with 
severe TB and may be a marker of failed previous treatments.  We explored these 
associations using multivariable logistic regression; however this analysis was 
limited by the small sample size, associations between all the included variables, 
and numeric challenges including zero-cells.  
 
A limitation of the study is the retrospective design.  There was limited information on 
adherence, which may have impacted on clinical and microbiologic outcomes.  The 
lack of a drug-susceptible TB control group prohibited us from concluding whether 
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outcomes in our cohort significantly differed from children with drug-susceptible TB. 
There may be limited generalizability of our findings to children treated in the 
community, where less severe TB would be expected and treatment responses may 
be more favourable given lower organism burden. 
 
CONCLUSIONS 
 
Although the impact of treatment regimens and treatment outcomes in this cohort 
should be interpreted with caution, our data has begun to fill an important gap in 
knowledge on the treatment of HRRS-TB in children. This is the largest study 
describing treatment and outcomes of HRRS-TB in children. As there are 
implications for preventive therapy and treatment in children exposed to and 
diseased due to HRRS-TB, the relevance of knowing the INH resistance pattern of 
the child and source case needs to be considered with the broad roll-out of Xpert 
MTB/RIF.  Our data raises sufficient concern to warrant further evaluation of the 
most appropriate treatment of HRRS-TB in children.   
 
 
  
Stellenbosch University  https://scholar.sun.ac.za
  10 
References 
1. Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int J 
Tuberc Lung Dis. 2004;8(5):636-47. 
2. World Health Organization. Global Tuberculosis Report 2014 Geneva, 
Switzerland: WHO; 2014 [Accessed February 25, 2015]. Available from: 
http://www.who.int/tb/publications/global_report/en/. 
3. Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant 
tuberculosis disease in children: systematic review and global estimates. Lancet. 
2014;383(9928):1572-9. 
4. Yuen CM, Jenkins HE, Rodriguez CA, Keshavjee S, Becerra MC. Global and 
Regional Burden of Isoniazid-Resistant Tuberculosis. Pediatrics. 2015;136(1):e50-
e9. 
5. Schaaf HS, Hesseling AC, Rautenbach C, Seddon JA. Trends in childhood 
drug-resistant tuberculosis in South Africa: a window into the wider epidemic? Int J 
Tuberc Lung Dis. 2014;18(7):770-3. 
6. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int 
J Tuberc Lung Dis. 2000;4(9):796-806. 
7. Donald PR, Schaaf HS. Old and new drugs for the treatment of tuberculosis in 
children. Paediatr Respir Rev. 2007;8(2):134-41. 
8. American Thoracic Society/Centers for Disease Control and 
Prevention/Infectious Diseases Society of America. Am Journal of Respir Crit Care 
Med. 2003;167(4):603-62. 
9. World Health Organization. Guidelines for the programmatic management of 
drug-resistant tuberculosis: Emergency Update 2008. Available from: 
http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf. 
10. Department of Health Republic of South Africa. Managment of Drug-Resistant 
Tuberculosis: Policy Guidelines 2011 [accessed 2012 May 15, 2012]. Available from: 
http://www.hst.org.za/sites/default/files/TBpolicy.pdf. 
11. World Health Organization. Guidance for national tuberculosis programs on 
the management of tuberculosis in children Geneva, Switzerland: WHO; 2006 
[Accessed May 25, 2012]. Available from: 
whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf?ua=1. 
Stellenbosch University  https://scholar.sun.ac.za
  11 
12. Tuberculosis. In: Larry K. Pickering, Carol J. Baker, David W. Kimberlin, 
editors. Red Book, 29th Edition: Report of the Committee on Infectious Diseases. 
American Academy of Pediatrics; 2012. p. 736-59. 
13. Hong Kong Chest Service/British Medical Research Council. Five-year follow-
up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary 
tuberculosis. Am J Resp Crit Care Med. 1987;136(6):1339-42. 
14. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to 
short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 
1986;133(3):423-30. 
15. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active 
tuberculosis in patients with previous treatment and/or with mono-resistance to 
isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000150. 
16. Steiner P, Rao M, Victoria M, Steiner M. Primary isoniazid-resistant 
tuberculosis in children. Clinical features, strain resistance, treatment, and outcome 
in 26 children treated at Kings County Medical Center of Brooklyn between the years 
1961 and 1972. Am Rev Respir Dis. 1974;110(3):306-11. 
17. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of 
tuberculosis and rifampin resistance. N Eng J Med. 2010;363(11):1005-15. 
18. Detjen AK, DiNardo AR, Leyden J, et al. Xpert MTB/RIF assay for the 
diagnosis of pulmonary tuberculosis in children: a systematic review and meta-
analysis. Lancet Respir Med. 2015;3(6):451-61. 
19. World Health Organization. Xpert MTB/RIF assay for the diagnosis of 
pulmonary and extrapulmonary TB in adults and children Geneva, Switzerland: 
WHO; 2014 [Accessed August 24, 2015]. Available from: 
http://apps.who.int/iris/bitstream/10665/112472/1/9789241506335_eng.pdf. 
20. Day C, Gray A, Budgell E. South African Health Review 2011. Durban: Health 
Systems Trust; 2010. Available from: http://www.hst.org.za/publications/south-
african-health-review-2011. 
21. Wiseman CA, Gie RP, Starke JR, et al. A proposed comprehensive 
classification of tuberculosis disease severity in children. Pediatr Infect Dis J. 
2012;31(4):347-52. 
22. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for 
weight, height, body mass index and head circumference fitted by maximum 
penalized likelihood. Stat Med. 1998;17(4):407-29. 
Stellenbosch University  https://scholar.sun.ac.za
  12 
23. Seddon JA, Perez-Velez CM, Schaaf HS, et al. Consensus statement on 
research definitions for drug-resistant tuberculosis in children. J Pediatric Infect Dis 
Soc. 2013;2(2):100-9. 
24. Seddon JA, Hesseling AC, Willemse M, Donald PR, Schaaf HS. Culture-
confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, 
and outcome. Clin Infect Dis. 2012;54(2):157-66. 
25. Seung KJ, Gelmanova IE, Peremitin GG, et al. The effect of initial drug 
resistance on treatment response and acquired drug resistance during standardized 
short-course chemotherapy for tuberculosis. Clin Infect Dis. 2004;39(9):1321-8. 
26. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. 
Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape 
Province, South Africa. Clin Infect Dis. 2011;53(4):369-72. 
27. Hiruy H, Rogers Z, Mbowane C, et al. Subtherapeutic concentrations of first-
line anti-TB drugs in South African children treated according to current guidelines: 
the PHATISA study. J Antimicrob Chemother. 2015;70(4):1115-23. 
28. Ramachandran G, Kumar AK, Bhavani PK, et al. Pharmacokinetics of first-line 
antituberculosis drugs in HIV-infected children with tuberculosis treated with 
intermittent regimens in India. Antimicrob Agents Chemother. 2015;59(2):1162-7. 
29. Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. High treatment 
success in children treated for multidrug-resistant tuberculosis: an observational 
cohort study. Thorax. 2014;69(5):458-64. 
30. Garcia-Prats AJ, Draper HR, Thee S, et al. The pharmacokinetics and safety 
of ofloxacin in children with drug-resistant tuberculosis. Antimicrob Agents 
Chemother. 2015 (in press). 
31. Garcia-Prats AJ, Willemse M, Seifart HI, et al. Acquired drug resistance 
during inadequate therapy in a young child with tuberculosis. Pediatr Infect Dis J. 
2014;33(8):883-5. 
32. Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP. Isoniazid 
resistance and death in patients with tuberculous meningitis: retrospective cohort 
study. BMJ. 2010;341:c4451. 
33. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing 
rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised 
controlled phase 2 trial. Lancet Infect Dis. 2013;13(1):27-35. 
Stellenbosch University  https://scholar.sun.ac.za
  13 
34. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-
thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era 
State of the Art. Int J Tuberc Lung Dis. 2004;8(4):392-402. 
Stellenbosch University  https://scholar.sun.ac.za
  14 
 
Table 1.  Demographic and clinical characteristics of children with culture-confirmed 
isoniazid-resistant rifampicin-susceptible tuberculosis at diagnosis (n=72) 
 n (%) 
Median age in months (IQR) 50.1 (21.5 – 102.5) 
Male sex 30 (42%) 
Identified potential TB source case  
None 28 (39%) 
One potential source case 34 (47%) 
Two potential source cases 10 (14%) 
Potential source case’s drug-susceptibility results (n=54)*  
Drug-susceptible (INH-susc, RIF-susc) 1 (2%) 
INH-monoresistant (INH-Res, RIF-susc) 13 (24%) 
Multidrug-resistant (INH-Res, RIF-Res) 8 (15%) 
RIF-monoresistant (INH-susc, RIF-Res) 1 (2%) 
Unknown 31 (57%) 
Previous TB treatment episode  
None 55 (76%) 
One episode 15 (21%) 
Two episodes 2 (3%) 
Positive Mantoux tuberculin skin test (n = 53 tested)* 43 (81%) 
Median weight-for-age Z-score (IQR) -2.01 (-3.25 to -0.99) 
Weight-for-age Z-score <-2 36 (50%) 
HIV-infected (n = 66 tested)* 12 (17%) 
Severe WHO immunologic stage at TB diagnosis  5 (42%) 
On ART before TB diagnosis 3 (25%) 
TB type  
PTB only 36 (50%) 
Both PTB and EPTB 24 (33%) 
EPTB only 12 (17%) 
Site of EPTB (n=37, more than one site is possible)*  
Miliary (no TB meningitis) 1 (3%) 
TB meningitis 11 (30%) 
Abdominal 6 (16%) 
Peripheral lymph node disease 11 (30%) 
Pleural effusion 3 (8%) 
Pericardial effusion 2 (5%) 
Bone/joint/spine 8 (22%) 
Other 2 (5%) 
Severe PTB (n=60 with PTB)* 36 (60%) 
AFB sputum smear-positive (n=56 tested)* 25 (45%) 
INH resistance mutation (n=38 tested)*  
inhA mutation 26 (68%) 
katG mutation 10 (26%) 
Both inhA and katG mutations 2 (5%) 
*indicates less than 72 had results 
IQR = interquartile range, INH = isoniazid, RIF = rifampicin, susc = susceptible, Res = 
resistant, WHO = World Health Organization, TB = tuberculosis, ART = antiretroviral 
therapy, PTB = pulmonary TB, EPTB = extrapulmonary TB, AFB = acid-fast bacilli 
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Table 2.  Description of children with isoniazid-resistant rifampicin-susceptible tuberculosis with recent previous TB treatment (<1 year prior) and 
those with death/treatment failure 
Age, gender HIV-status Case description Outcome 
Patients previously receiving any TB treatment 1 year prior to HRRS-TB episode (n=8) 
12 year F HIV-uninfected Completed 18 months of treatment for confirmed MDR-PTB just prior to diagnosis of HRRS-
TB episode; had new HRRS-TB exposure 
Completed MDR-TB 
treatment 
2 year F HIV-uninfected Diagnosed with PTB 9 months prior to HRRS-TB episode, interrupted treatment after only 3 
months of standard TB treatment 
Lost-to-follow-up, drug-
susceptible TB treatment 
1 year F 
 
HIV-uninfected Developed HRRS-TB 5 months into course of isoniazid preventive therapy Failed isoniazid preventive 
therapy 
7 year F HIV-infected Completed 6 months of standard TB treatment for drug-susceptible TB 4 months prior to 
HRRS-TB episode 
Completed drug-susceptible 
TB treatment 
4 month F 
 
HIV-uninfected Developed HRRS-TB meningitis roughly 1 month after starting isoniazid preventive therapy Failed isoniazid-preventive 
therapy 
11 year F 
 
HIV-uninfected Completed 6 months of standard drug-susceptible TB treatment 4 months prior to HRRS-TB 
episode; had poor radiological and clinical response to this treatment 
Completed drug-susceptible 
TB treatment 
14 year F 
 
HIV-uninfected Completed 6 months of standard drug-susceptible TB treatment 2 months prior to HRRS-TB 
episode; had poor clinical response to treatment 
Completed drug-susceptible 
TB treatment 
13 year F 
 
HIV-uninfected Completed >5 months of standard drug-susceptible TB treatment for extensive PTB just 
prior to confirmed HRRS-TB episode; was smear positive at month 5 of treatment 
Failed drug-susceptible TB 
treatment 
Patients with death or treatment failure from HRRS TB episode (n=4) 
4 year F HIV-infected Presented with severe PTB, Stage 2 TBM and severe immunosuppression (CD4 81, 
19.6%); promptly started RHZ-ethionamide, but died in hospital 5 days after admission. 
Death 
12 year M HIV-infected After 5 months of community-based treatment with RHZE for confirmed HRRS-TB, 
remained sputum culture positive so started on empiric MDR-TB treatment, but DST 
continued to show HRRS-TB; treated successfully with a fluoroquinolone and other 
secondline. 
Treatment failure 
20 month M HIV-uninfected Treated with RHZ for extensive PTB and despite a poor treatment response, was switched 
to a 2-drug continuation phase (RH) after 2 months.  Had worsening lung disease with 
persistent culture positivity; eventually was diagnosed with TBM and confirmed MDR-TB. 
Treatment failure, acquired 
rifampicin resistance 
6 year F HIV-infected Treated with RHZ at her community clinic for extensive PTB, but after confirmation of 
HRRS-TB and persistent culture positivity a fluoroquinolone and other secondline TB meds 
were added; she improved slowly and ultimately completed 20 months of treatment. 
Treatment failure 
M = male, F = female, TB = tuberculosis, HRRS = isoniazid-resistant rifampicin susceptible, PTB = pulmonary TB, R=rifampicin, H=isoniazid, Z = 
pyrazinamide, E = ethambutol, TBM = TB meningitis, MDR = multidrug-resistant 
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Table 3.  Treatment regimens and clinical outcomes in children with culture-
confirmed isoniazid-resistant rifampicin-susceptible tuberculosis (n = 70) 
 
n (%) 
Treatment characteristics (n=70 with some data on treatment)  
Median total duration of treatment in months [(QR) [n=62] 11.3 (9 – 12.3) 
Median duration of HRRS treatment in months (IQR) [n=58] 10.5 (8.7 – 12.2) 
Initiated treatment with RHZ 25 (36%) 
Treated with RHZ ≥ 1month 21 (30%) 
Treated with RH in continuation phase (n=63) 6 (10%) 
Treated with ≥6HRZE 6 (9%) 
Treated with a fluoroquinolone, with or without other 2nd-
lines 
52 (74%) 
  
Clinical outcomes (n = 63; 9 with unknown outcome)  
Favourable 55 (88%) 
Cure 22 (31%) 
Probable cure 7 (10%) 
Treatment completed 26 (36%) 
Unfavorable 8 (12%) 
Lost-to-follow-up 3 (4%) 
Death 1 (1%) 
Treatment failure 3 (4%) 
Transferred out 1 (1%) 
IQR = interquartile range, HRRS = isoniazid-resistant rifampicin susceptible, RHZ = 
rifampicin-isoniazid-pyrazinamide, E = ethambutol 
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Table 4. Characteristics associated with unfavourable treatment outcome and prolonged culture positivity among children with 
culture-confirmed isoniazid-resistant rifampicin-susceptible tuberculosis 
 
Clinical outcomes 
 
Microbiological outcomes 
 
n 
Favourable 
Outcome 
(n=55) 
Unfavourable 
Outcome 
(n=8) p-value 
 
n 
Follow-up 
culture not 
positive at 
≥2 months 
(n=27) 
Follow-up  
culture 
positive at 
≥2 months 
(n=10) p-value 
Median age in months (IQR) 63 
49.7  
(24.9-91.3) 
38.8  
(20.7-66.5) 
p=0.53 
 
37 
46.3  
(18.9-107) 
131.2  
(82.1-146) 
p=0.008 
Male sex 63 22 (40%) 4 (50%) p=0.43  37 11 (41%) 3 (30%) p=0.71 
Known previous treatment 63 12 (22%) 3 (38%) p=0.29  37 7 (26%) 7 (70%) p=0.023 
WAZ <-2 63 26 (55%) 6 (75%) p=0.26  37 15 (56%) 8 (80%) p=0.26 
Any EPTB 63 31 (57%) 4 (50%) p=0.51  37 12 (24%) 2 (20%) p=0.26 
HIV-infected  58 9 (18%) 3 (43%) p=0.15  36 3 (12%) 3 (30%) p=0.32 
Identified potential source case 63 31 (56%) 7 (88%) p=0.13  37 16 (59%) 7 (70%) p=0.71 
Severe PTB  53 26 (58%) 5 (71%) p=0.38  37 16 (59%) 10 (100%) p=0.018 
Sputum smear positive  48 18 (43%) 3 (43%) p=1.00  34 10 (42%) 7 (70%) p=0.26 
Any katG gene mutation (vs inhA 
only)  
38 9 (28%) 3 (50%) p=0.36 
 
21 3 (19%) 2 (40%) p=0.55 
RHZ>1m in intensive phase 63 16 (29%) 3 (38%) p=0.46  37 3 (11%) 3 (30%) p=0.31 
Received FQN-containing regimen 63 41 (75%) 6 (75%) p=1.00  37 24 (89%) 7 (70%) p=0.31 
IQR = interquartile range, WAZ = weight-for-age z-score, EPTB = extrapulmonary tuberculosis, PTB = pulmonary tuberculosis, RHZ = 
rifampicin-isoniazid-pyrazinamide, FQN = fluoroquinolone 
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Figure'1.'Posi- ve'respiratory'cultures'for'Mycobacterium-tuberculosis-as'percentages'of'all'pulmonary'
tuberculosis'(PTB)'cases'and'of'follow?up'(F/U)'respiratory'cultures'among'children'with'culture'confirmed'
isoniazid?resistant'rifampicin?suscep- ble'TB'
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